Postbiotic Akkermansia Supports Metabolic, Endocrine, Microbiome Benefits in Women with PMOS: Study
Published: October 14, 2026
Nutraceuticals World covers a new clinical study on AKK Probio, the postbiotic Akkermansia muciniphila ingredient distributed in the U.S. by Maypro, in women with polyendocrine metabolic ovarian syndrome (PMOS).
PMOS, formerly called polycystic ovary syndrome, affects about one in eight women and was renamed in 2026 to reflect its effects across multiple body systems.
Published in Clinical Nutrition, the 12-week randomized controlled trial enrolled 100 women with obesity-associated PMOS on standard oral contraceptive therapy, who added either AKK Probio or a placebo.
The AKK Probio group showed lower fasting insulin, insulin resistance, LDL cholesterol and testosterone, along with improvements in acne, hirsutism and menstrual regularity.
Lauren Clardy, Maypro’s senior director of scientific affairs, pointed to the breadth of the response across metabolic, reproductive and gut microbiome measures.
